Company News

Share this article:

Maryland-based Osiris Therapeutics announced the creation of a new biosurgery division focused on developing and marketing high-end biological products used in surgical procedures. The company hopes to build on the success of Osteocel, an implantable product launched in 2005. Osteocel generated over $40 million in revenue before being sold in 2008 to Nuvasive for “up to $85 million,” according to a company release.

California-based Eiger BioPharmaceuticals acquired an exclusive license from Stanford University for its hepatitis C virus technology. The technology was discovered in the lab of Stanford scientist and Eiger founder Jeffrey Glenn. Financial terms of the deal were not disclosed.


Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.